

Joshua D Grill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4414259/publications.pdf>

Version: 2024-02-01

66
papers

1,717
citations

279798

23
h-index

302126

39
g-index

66
all docs

66
docs citations

66
times ranked

2036
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Prodromal Alzheimer Disease With Avagacestat. <i>JAMA Neurology</i> , 2015, 72, 1324.	9.0	179
2	Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 34.	6.2	144
3	Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 26.	6.2	106
4	Current therapeutic targets for the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 711-728.	2.8	101
5	Facilitating Alzheimer Disease Research Recruitment. <i>Alzheimer Disease and Associated Disorders</i> , 2014, 28, 1-8.	1.3	86
6	African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 57-64.	3.7	71
7	Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial. <i>JAMA Network Open</i> , 2021, 4, e2114364.	5.9	68
8	Effect of study partner on the conduct of Alzheimer disease clinical trials. <i>Neurology</i> , 2013, 80, 282-288.	1.1	58
9	Estimating sample sizes for prodementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. <i>Neurobiology of Aging</i> , 2013, 34, 62-72.	3.1	49
10	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. <i>JAMA Neurology</i> , 2020, 77, 1504.	9.0	48
11	Communicating mild cognitive impairment diagnoses with and without amyloid imaging. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 35.	6.2	46
12	Changes in regional cerebral blood flow associated with a 45-day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study. <i>Experimental Gerontology</i> , 2018, 111, 118-121.	2.8	45
13	The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. <i>Nature Reviews Neurology</i> , 2021, 17, 523-524.	10.1	44
14	Constructing a Local Potential Participant Registry to Improve Alzheimer's Disease Clinical Research Recruitment. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1055-1063.	2.6	37
15	Why are Spousal Caregivers More Prevalent than Nonspousal Caregivers as Study Partners in AD Dementia Clinical Trials?. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 70-74.	1.3	35
16	Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials. <i>Neurobiology of Aging</i> , 2016, 39, 147-153.	3.1	35
17	Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment. <i>Alzheimer's and Dementia</i> , 2013, 9, 356.	0.8	33
18	Attitudes toward clinical trials across the Alzheimer's disease spectrum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 81.	6.2	33

#	ARTICLE	IF	CITATIONS
19	Patient and caregiver reactions to clinical amyloid imaging. <i>Alzheimer's and Dementia</i> , 2017, 13, 924-932.	0.8	30
20	Should we disclose amyloid imaging results to cognitively normal individuals?. <i>Neurodegenerative Disease Management</i> , 2013, 3, 43-51.	2.2	29
21	Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 15-22.	2.4	29
22	Study partners: essential collaborators in discovering treatments for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 101.	6.2	29
23	Are Patients Whose Study Partners Are Spouses More Likely to be Eligible for Alzheimer's Disease Clinical Trials. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 334-340.	1.5	25
24	Racial and ethnic differences in older adults' willingness to be contacted about Alzheimer's disease research participation. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12023.	3.7	25
25	Retention of Alzheimer Disease Research Participants. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 299-306.	1.3	24
26	Study partners should be required in preclinical Alzheimer's disease trials. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 93.	6.2	22
27	Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 125.	6.2	20
28	A Preliminary Study of Clinical Trial Enrollment Decisions Among People With Mild Cognitive Impairment and Their Study Partners. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 322-332.	1.2	20
29	Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 39.	6.2	19
30	The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease. <i>Contemporary Clinical Trials</i> , 2013, 36, 256-262.	1.8	18
31	Recruiting to preclinical Alzheimer's disease clinical trials through registries. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 205-212.	3.7	17
32	Choosing Alzheimer's disease prevention clinical trial populations. <i>Neurobiology of Aging</i> , 2014, 35, 466-471.	3.1	15
33	Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer's disease: study partner vs. participant accuracy. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 85.	6.2	13
34	Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer's trials. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 92.	6.2	13
35	Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 104-112.	1.3	12
36	Recruiting the Oldest-old for Clinical Research. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 160-162.	1.3	11

#	ARTICLE	IF	CITATIONS
37	Recruitment and retention of participant and study partner dyads in two multinational Alzheimer's disease registration trials. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 16.	6.2	11
38	A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 50.	6.2	10
39	Frequency and Impact of Informant Replacement in Alzheimer Disease Research. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 242-248.	1.3	10
40	Participant-Informant Relationships Affect Quality of Life Ratings in Incipient and Clinical Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 297-307.	1.2	10
41	Attitudes toward Potential Participant Registries. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 939-946.	2.6	9
42	Research Attitudes Questionnaire scores predict Alzheimer's disease clinical trial dropout. <i>Clinical Trials</i> , 2021, 18, 237-244.	1.6	9
43	Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing. <i>Alzheimer's and Dementia</i> , 2022, 18, 1969-1979.	0.8	8
44	Does Alzheimer Disease Pathologic Change Underlie Subjective Cognitive Complaints?. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 350-352.	1.3	5
45	Public Understanding and Opinions regarding Genetic Research on Alzheimer's Disease. <i>Public Health Genomics</i> , 2018, 21, 228-237.	1.0	5
46	Asian Americans and Pacific Islanders' perspectives on participating in the CARE recruitment research registry for Alzheimer's disease and related dementias, aging, and caregiving research. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12195.	3.7	5
47	Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials. <i>Neurology</i> , 2021, 97, 496-500.	1.1	5
48	Reasons for undergoing amyloid imaging among cognitively unimpaired older adults. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1646-1655.	3.7	5
49	Online seminars as an information source for direct-to-consumer stem cell therapy. <i>Regenerative Medicine</i> , 2022, 17, 81-90.	1.7	5
50	Perceptions of Research Burden and Retention Among Participants in ADRC Cohorts. <i>Alzheimer Disease and Associated Disorders</i> , 0, Publish Ahead of Print, .	1.3	5
51	Does Study Partner Type Impact the Rate of Alzheimer's Disease Progression?. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 507-514.	2.6	4
52	Direct Mail Recruitment to a Potential Participant Registry. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 80-83.	1.3	4
53	Retaining Participants in Longitudinal Studies of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 945-955.	2.6	4
54	On the design of early-phase Alzheimer's disease clinical trials with cerebrospinal fluid tau outcomes. <i>Clinical Trials</i> , 2021, 18, 714-723.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Should persons with autosomal dominant AD be included in clinical trials?. Alzheimer's Research and Therapy, 2011, 3, 18.	6.2	2
56	Consider the Source. Alzheimer Disease and Associated Disorders, 2015, 29, 364.	1.3	2
57	Youâ€™ve Got a Friend in Me: How Cognitively Unimpaired Older Adults Select a Study Partner to Participate with Them in Alzheimerâ€™s Disease Research. Journal of Alzheimer's Disease, 2022, , 1-13.	2.6	2
58	Strategies Associated with Retaining Participants in the Longitudinal National Alzheimerâ€™s Coordinating Center Uniform Data Set Study. Journal of Alzheimer's Disease, 2022, 87, 1557-1566.	2.6	2
59	Dyadic Enrollment in a Phase 3 Mild Cognitive Impairment Clinical Trial. Alzheimer Disease and Associated Disorders, 2022, Publish Ahead of Print, .	1.3	2
60	A Scoping Review of Dietary Factors Conferring Risk or Protection for Cognitive Decline in APOE Î¼4 Carriers. Journal of Nutrition, Health and Aging, 2021, 25, 1167-1178.	3.3	1
61	S3-02-04: Ethics in Alzheimer's disease prevention clinical trial design. , 2015, 11, P211-P211.		0
62	P3â€™06: Racial Differences in Willingness to Enroll in Preclinical Alzheimer's Disease Clinical Trials. Alzheimer's and Dementia, 2016, 12, P819.	0.8	0
63	P4â€™28: Communicating Mild Cognitive Impairment Diagnosis with and Without Amyloid Imaging: Recommendations From An Expert Workgroup. Alzheimer's and Dementia, 2016, 12, P1160.	0.8	0
64	Response to â€œAvoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosureâ€• Alzheimer's Research and Therapy, 2019, 11, 51.	6.2	0
65	Diversifying Recruitment Registries: Considering Neighborhood Health Metrics. journal of prevention of Alzheimer's disease, The, 2022, 9, 1-7.	2.7	0
66	Alzheimerâ€™s Disease Clinical Trial Study Partners. , 2022, , 333-342.		0